Viyash Scientific Ltd Board and Executive Decisions

Shareholders of Viyash Scientific Ltd are being asked to approve significant corporate actions, including the appointment of two new directors and a one-time performance incentive for the company's Whole-time Director & CEO. The company also presented a financial snapshot indicating a substantial turnaround.

Reader Takeaway: Improved financials and deleveraging are positive; director appointments reflect private equity influence.

What just happened

Viyash Scientific Ltd has issued a Postal Ballot Notice seeking shareholder approval for several key decisions. These include the appointment of Mr. Amit Jain and Mr. Abhiroop Jayanthi as Non-Executive, Non-Independent Directors. Both individuals are nominees of The Carlyle Group, indicating ongoing strategic input from the private equity investor. Additionally, shareholders are requested to approve a one-time performance incentive of ₹4 crore for Mr. Rajaram Narayanan, the Whole-time Director & CEO of the Animal Health division.

Why this matters

The proposed director appointments signal continued strategic oversight by a major stakeholder. The performance incentive for the CEO is linked to the company's value creation and successful merger execution, highlighting management's role in recent operational improvements. The company's reported financial turnaround, from a significant loss in FY23 to a profit in H1 FY2025-26, is a key indicator of improved business performance.

The backstory

In the period leading up to its merger, Viyash Scientific has reported a notable financial transformation. The company moved from a loss after tax of ₹122 crore in the full year FY 23 to a profit of ₹37.2 crore in the first half of FY 2025-26. This turnaround is supported by an expansion in gross margins from 41.3% to 48.3% and a significant reduction in net debt relative to EBITDA, from 4.7x to 1.7x.

What changes now

Upon shareholder approval, the board composition will be updated with the induction of the two new directors. The proposed incentive payment will be made to the CEO, subject to the approval, as a recognition of past performance and contribution to the merger and subsequent operational improvements. The financial metrics presented suggest a strengthening operational and financial footing for the company.

Risks to watch

While the financial turnaround is positive, the approval of executive incentives, especially when statutory limits on remuneration might be a factor due to past 'inadequate profits', requires careful scrutiny by shareholders. The successful integration and realization of synergies from the merger remain a critical ongoing factor for sustained performance.

Peer comparison

No direct peer comparison data is provided in the filing. However, the reported improvement in margins and debt reduction are generally viewed positively within the industry. The involvement of a private equity firm like The Carlyle Group suggests strategic growth ambitions.

Context metrics (time-bound)

• Revenue: FY 23 ₹1,420.9 Cr; H1 FY 2025-26 ₹865.4 Cr.
• EBITDA: FY 23 ₹75.6 Cr; H1 FY 2025-26 ₹125.9 Cr.
• Profit After Tax: FY 23 (₹122.0) Cr; H1 FY 2025-26 ₹37.2 Cr.
• Gross Margin: FY 23 41.3%; H1 FY 2025-26 48.3%.
• Net Debt / EBITDA: FY 23 4.7x; H1 FY 2025-26 1.7x.

What to track next

Investors should closely monitor the outcomes of the postal ballot for director appointments and the CEO incentive. Continued improvement in financial results, margin expansion, and further debt reduction will be key indicators of the company's forward momentum.